Discovery and lead optimization

The right data

Accelerate with confidence

Schedule a call to learn how IPST can deliver your preclinical research on-time and on-budget. Our 24 years of experience will strengthen your drug development pipeline. Analysis & guidance included — always.

Dedicated to scientific excellence since 1999, IPS Therapeutique (IPST) is a contract research organization (CRO) specialized in the preclinical evaluation of the efficacy and safety of new drugs using validated and highly predictive models. IPST’s science has been featured in more than 200 peer-reviewed articles since 2000.

01 / Cardiovascular

Cardiovascular diseases

We leverage our world-class expertise on cardiovascular diseases, e.g., pulmonary arterial hypertension, myocardial infarction, hemorrhagic shock, acute kidney injury, to craft tailored protocols designed in collaboration with you.

02 / Inflammatory

Inflammatory disorders

We leverage our world-class expertise on inflammatory disorders, e.g., diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, liver fibrosis, cholestatic liver disease, to craft tailored protocols designed in collaboration with you.

03 / Respiratory

Respiratory diseases

We leverage our world-class expertise on respiratory diseases e.,g., chronic obstructive pulmonary disease, asthma, allergic rhinitis, pulmonary fibrosis, to craft tailored protocols designed in collaboration with you.

04 / Bleeding

Bleeding disorders

We leverage our world-class expertise on bleeding disorders, e.g., hemophilia, sickle cell anemia, immune thrombocytopenia, von Willebrand disease, to craft tailored protocols designed in collaboration with you.

Reduce the costs of early drug development

IPST will shorten the time spent with a risky molecule and lower the costs of the Discovery and Lead Optimization phase of your project.

Discover our featured white papers

Learn more about our ongoing scientific research.

Learn more

The benefits of inhalation models – A conversation with IPST’s Dan Salvail

by Dany Salvail Ph.D., Vice-President.

Published on May 1, 2022

Female rats respond better to Sildenafil treatment in SuHx-induced PAH model

by Charles-E. Laurent Ph.D., Director of In-Vivo Pharmacology

Published on May 1, 2020